Skip to main content
SpringerLink
Log in

Drug effects on the liver

An updated tabular compilation of drugs and drug-related hepatic diseases

  • Review Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Generic and chemical names of drugs and the possible adverse effects of these drugs on the human liver are tabulated. Most drugs compiled in these tables have been approved by the Federal Drug Administration. They are currently available in the United States, and they are listed in the 1983Physicians' Desk Reference. Some important investigational drugs are listed also. The tables include: (1) generic names of drugs that have caused a characteristic morphologic change, such as granulomatous hepatitis; (2) morphologic diagnoses that have been documented after administration of each drug; and (3) references that can be matched to each drug and to its effects on the liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ludwig J: Drug effects on the liver: A tabular compilation of drugs and drug-related hepatic diseases. Dig Dis Sci 24:785–796, 1979

    Google Scholar 

  2. Physicians' Desk Reference, 37th ed. Oradell, New Jersey, Medical Economics Co., 1983

  3. Science Citation Index. Philadelphia, Institute for Scientific Information

  4. Wright JM, Stokes EF, Sweeney VP: Isoniazid-induced carbamazepine toxicity and vice versa. A double drug interaction. N Engl J Med 307:1325–1327, 1982

    Google Scholar 

  5. Popper H, Geller SA: Pathogenetic considerations in the histologic diagnosis of drug-induced liver injury.In Progress in Surgical Pathology, Vol 3. CM Fenoglio, M Wolff (eds.). New York, Masson Publishing, 1981, pp 233–246

    Google Scholar 

  6. Zimmerman HJ: Drug-induced liver disease: An overview. Semin Liver Dis 1:93–103, 1981

    Google Scholar 

  7. Black M, Cornell JF, Rabin L, Shachter, N: Late presentation of acetaminophen hepatotoxicity. Dig Dis Sci 27:370–374, 1982

    Google Scholar 

  8. Symon DNK, Gray ES, Hanmer OJ, Russell G: Fatal paracetamol poisoning from benorylate therapy in child with cystic fibrosis. Lancet 2:1153–1154, 1982 (letter)

    Google Scholar 

  9. Bonkowsky HL, Mudge GH, McMurtry RJ: Chronic hepatic inflammation and fibrosis due to low doses of paracetamol. Lancet 1:1016–1018, 1978

    Google Scholar 

  10. Gerber MA, Kaufmann H, Klion F, Alpert LI: Acetaminophen associated hepatic injury. Report of two cases showing unusual portal tract reactions. Hum Pathol 11:37–42, 1980

    Google Scholar 

  11. Arthurs Y, Fielding JF: Paracetamol and chronic liver disease. J Ir Med Assoc 73:273–274, 1980

    Google Scholar 

  12. Johnson GK, Tolman KG: Chronic liver disease and acetaminophen. Ann Intern Med 87:302–304, 1977

    Google Scholar 

  13. Goldstein MJ, Rothenberg AJ: Jaundice in a patient receiving acetohexamide. N Engl J Med 275:97–99, 1966

    Google Scholar 

  14. Houghton AN, Shafi, N, Rickles FR: Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease. A case report. Cancer 44:2324–2329, 1979

    Google Scholar 

  15. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG: Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 95:588–590, 1981

    Google Scholar 

  16. Butler RC, Shah SM, Grunow WA, Texter EC Jr: Massive hepatic necrosis in a patient receiving allopurinol. JAMA 237:473–474, 1977

    Google Scholar 

  17. Klatskin G: Toxic and drug-induced hepatitis.In Diseases of the Liver, 4th ed. L. Schiff (ed.). Philadelphia, JB Lippincott, 1975, pp 604–710

    Google Scholar 

  18. Lang PG Jr: Severe hypersensitivity reactions to allopurinol. South Med J 72:1361–1368, 1979

    Google Scholar 

  19. Medline A, Cohen LB, Tobe BA, Sellers EM: Liver granulomas and allopurinol. Br Med J 1:1320–1321, 1978

    Google Scholar 

  20. Popper H, Rubin E, Gardiol D, Schaffner F, Paronetto F: Drug-induced liver disease. A penalty for progress. Arch Intern Med 115:128–136, 1965

    Google Scholar 

  21. Kent G, Orfei E: Hepatic manifestations of toxic and therapeutic agents.In Laboratory Diagnosis of Diseases Caused by Toxic Agents. FW Sunderman, FW Sunderman Jr (eds.). St. Louis, Warren H. Green, 1970, pp 460–468

    Google Scholar 

  22. Simpson DG, Walker JH: Hypersensitivity to para-aminosalicylic acid. Am J Med 29:297–306, 1960

    Google Scholar 

  23. Cunningham ML: Acute hepatic necrosis following treatment with amitriptyline and diazepam. Br J Psychiatry 111:1107–1109, 1965

    Google Scholar 

  24. Yon J, Anuras S: Hepatitis caused by amitriptyline therapy. JAMA 232:833–834, 1975

    Google Scholar 

  25. Biagi RW, Bapat BN: Intrahepatic obstructive jaundice from amitriptyline. Br J Psychiatry 113:1113–1114, 1967

    Google Scholar 

  26. Herlong HF, Reid PR, Boitnott JK, Maddrey WC: Aprindine hepatitis. Ann Intern Med 89:359–361, 1978

    Google Scholar 

  27. Stoel I, Hagemeijer F: Aprindine: A review. Eur Heart J 1:147–156, 1980

    Google Scholar 

  28. Haskell CM:l-Asparaginase: Human toxicology and single agent activity in nonleukemic neoplasms. Cancer Treat Rep 65(Suppl 4):57–59, 1981

    Google Scholar 

  29. Seaman WE, Ishak KG, Plotz PH: Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 80:1–8, 1974

    Google Scholar 

  30. Sbarbaro JA, Bennett RM: Aspirin hepatotoxicity and disseminated intravascular coagulation. Ann Intern Med 86:183–185, 1977

    Google Scholar 

  31. Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 141:333–342, 1981

    Google Scholar 

  32. McMaster KR III, Hennigar GR: Drug-induced granulomatous hepatitis. Lab Invest 44:61–73, 1981

    Google Scholar 

  33. Halpin TJ, Holtzhauer FJ, Campbell RJ, Hall LJ, Correa-Villaseñor A, Lanese R, Rice J, Hurwitz ES: Reye's syndrome and medication use. JAMA 248:687–691, 1982

    Google Scholar 

  34. CDC. Surgeon General's advisory on the use of salicylates and Reye syndrome. Morbidity and Mortality Weekly Report 31:289–290, 1982

    Google Scholar 

  35. Peterson BA, Bloomfield CD, Gottlieb AJ, Coleman M, Greenberg MS: 5-Azacitidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: A cancer and leukemia group B pilot study. Cancer Treat Rep 66:563–566, 1982

    Google Scholar 

  36. Zarday Z, Veith FJ, Gliedman ML, Soberman R: Irreversible liver damage after azathioprine. JAMA 222:690–691, 1972

    Google Scholar 

  37. Haas J, Patzold U, Stamm T: Intrahepatische Cholestase, eine allergische Reaktion bei Azathioprin-Therapie. Dtsch Med Wochenschr 103:1576–1577, 1978

    Google Scholar 

  38. Weitz H, Gokel JM, Loeschke K, Possinger K, Eder M: Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Arch (Pathol Anat) 395:245–256, 1982

    Google Scholar 

  39. Marubbio AT, Danielson B: Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine. Gastroenterology 69:739–743, 1975

    Google Scholar 

  40. Degott C, Rueff B, Kreis H, Duboust A, Potet F, Benhamou JP: Peliosis hepatis in recipients of renal transplants. Gut 19:748–753, 1978

    Google Scholar 

  41. Zucker P, Daum F, Cohen MI: Fatal carbamazepine hepatitis. J Pediatr 91:667–668, 1977

    Google Scholar 

  42. Hopen G, Nesthus I, Laerum OD: Fatal carbamazepine-associated hepatitis. Report of two cases. Acta Med Scand 210:333–335, 1981

    Google Scholar 

  43. Ramsay ID: Carbamazepine-induced jaundice. Br Med J 4:155, 1967

    Google Scholar 

  44. Levy M, Goodman MW, Van Dyne BJ, Sumner HW: Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 95:64–65, 1981

    Google Scholar 

  45. Mitchell MC, Boitnott JK, Arregui A, Maddrey WC: Granulomatous hepatitis associated with carbamazepine therapy. Am J Med 71:733–735, 1981

    Google Scholar 

  46. Schaffner F, Raisfeld IH: Drugs and the liver: A review of metabolism and adverse reactions. Adv Intern Med 15:221–251, 1969

    Google Scholar 

  47. Wilson FM, Belamaric J, Lauter CB, Lerner AM: Anicteric carbenicillin hepatitis. Eight episodes in four patients. JAMA 232:818–821, 1975

    Google Scholar 

  48. McIntyre RE, Magidson JG, Austin GE, Gale RP, Fatal veno-occlusive disease of the liver following high-dose 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and autologous bone marrow transplantation. Am J Clin Pathol 75:614–617, 1981

    Google Scholar 

  49. Ammann R, Neftel K, Hardmeier TH, Reinhardt M: Cephalosporin-induced cholestatic jaundice. Lancet 2:336–337, 1982 (letter)

    Google Scholar 

  50. Bateson MC, Hopwood D, Bouchier IAD: Effect of gallstone-dissolution therapy on human liver structure. Am J Dig Dis 22:293–299, 1977

    Google Scholar 

  51. Fisher RL, Anderson DW, Boyer JL, Ishak K, Klatskin G, Lachin JM, Phillips MJ, and the Steering Committee for the National Cooperative Gallstone Study Group: A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: The National Cooperative Gallstone Study. Hepatology 2:187–201, 1982

    Google Scholar 

  52. Amromin GD, Deliman RM, Shanbrom E: Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 42:401–410, 1962

    Google Scholar 

  53. Pickering D: Hepatic necrosis after chlordiazepoxide therapy. N Engl J Med 274:1449, 1966 (letter)

    Google Scholar 

  54. Abbruzzese A, Swanson J: Jaundice after therapy with chlordiazepoxide hydrochloride. N Engl J Med 273:321–322, 1965

    Google Scholar 

  55. Husebye, KO: Jaundice with persisting pericholangiolitic inflammation in a patient treated with chlorothiazide. Report of a case. Am J Dig Dis 9:439–446, 1964

    Google Scholar 

  56. Belt RJ, McGregor D, Haas CD, Bhatia PS: Cholestatic jaundice associated with chlorozotocin. Cancer Treat Rep 64:1235–1239, 1980

    Google Scholar 

  57. Russell RI, Allan JG, Patrick R: Active chronic hepatitis after chlorpromazine ingestion. Br Med J 1:655–656, 1973

    Google Scholar 

  58. Ishak KG, Irey NS: Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients. Arch Pathol 93:283–304, 1972

    Google Scholar 

  59. Irani SK, Dobbins WO III: Hepatic granulomas: A review of 73 patients from one hospital and survey of the literature. J Clin Gastroenterol 1:131–143, 1979

    Google Scholar 

  60. Reichel J, Goldberg SB, Ellenberg M, Schaffner F: Intrahepatic cholestasis following administration of chlorpropamide. Report of a case with electron microscopic observations. Am J Med 28:654–660, 1960

    Google Scholar 

  61. Bateman JC, Barberio JR, Cromer JK, Klopp CT: Investigation of mechanism and type of jaundice produced by large doses of parenterally administered aureomycin. Antibiot Chemother 3:1–15, 1953

    Google Scholar 

  62. Sborov VM, Sutherland DA: Fatty liver following aureomycin and terramycin therapy in chronic hepatic disease. Gastroenterology 18:598–605, 1951

    Google Scholar 

  63. Ruiz Del Arbol L, Moreira V, Moreno A, Hernández Ranz F, Cano A, García Plaza A: Bridging hepatic necrosis associated with cimetidine. Am J Gastroenterol 74:267–269, 1980

    Google Scholar 

  64. Lorenzini I, Jezequel AM, Orlandi F: Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury. Dig Dis Sci 26:275–280, 1981

    Google Scholar 

  65. Bodenheimer HC Jr, Thayer WR Jr: Hemochromatosis associated with chronic cimetidine therapy? J Clin Gastroenterol 3:83–85, 1981

    Google Scholar 

  66. Cavalli F, Tschopp L, Sonntag RW, Zimmermann A: A case of liver toxicity followingcis-dichlorodiammineplatinum(II) treatment. Cancer Treat Rep 62:2125–2126, 1978 (letter)

    Google Scholar 

  67. Mori H, Tanaka T, Sugie S, Takahashi M: Adenoma with multiple hyperplastic nodules in noncirrhotic liver possibly related to long-term administration of a hypolipidemic drug. Acta Pathol Jpn 32:671–675, 1982

    Google Scholar 

  68. Pessayre D, Degos F, Feldmann G, Degott C, Bernuau J, Benhamou J-P: Chronic active hepatitis and giant multinucleated hepatocytes in adults treated with clometacin. Digestion 22:66–72, 1981

    Google Scholar 

  69. Parker JLW: Potassium clorazepate (Tranxene)-induced jaundice. Postgrad Med J 55:908–910, 1979

    Google Scholar 

  70. Zafrani ES, Pinaudeau Y, Le Cudonnec B, Julien M, Dhumeaux D: Focal hemorrhagic necrosis of the liver. A clinicopathological entity possibly related to oral contraceptives. Gastroenterology 79:1295–1299, 1980

    Google Scholar 

  71. Ishak KG: Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1:116–128, 1981

    Google Scholar 

  72. Camilleri M, Schafler K, Chadwick VS, Hodgson HJ, Weinbren K: Periportal sinusoidal dilatation, inflammatory bowel disease, and the contraceptive pill. Gastroenterology 80:810–815, 1981

    Google Scholar 

  73. Alpert LI: Veno-occlusive disease of the liver associated with oral contraceptives: Case report and review of literature. Hum Pathol 7:709–718, 1976

    Google Scholar 

  74. Lalonde G, Théoret G, Daloze P, Bettez P, Katz SS: Inferior vena cava stenosis and Budd-Chiari syndrome in a woman taking oral contraceptives. Gastroenterology 82:1452–1456, 1982

    Google Scholar 

  75. Helling TS, Wood WG: Oral contraceptives and cancer of the liver: A review of two additional cases. Am J Gastroenterol 77:504–508, 1982

    Google Scholar 

  76. Horri K, Yasui M, Adachi Y, Yamamoto T, Ishida O, Itoh H: An autopsy case of primary hepatoma associated with an oral contraceptive. Hepato-Gastroenterol 29:187–190, 1982

    Google Scholar 

  77. Littlewood ER, Barrison IG, Murray-Lyon IM, Paradinas FJ: Cholangiocarcinoma and oral contraceptives. Lancet 1:310–311, 1980

    Google Scholar 

  78. Ladaga, L, Kay S, Melcher M, King JN: Combined epithelial and sarcomatous elements in a liver cancer associated with oral contraceptive use. Am J Surg Pathol 3:185–190, 1979

    Google Scholar 

  79. Monroe PS, Riddell RH, Siegler M, Baker AL: Hepatic angiosarcoma. Possible relationship to long-term oral contraceptive ingestion. JAMA 246:64–65, 1981

    Google Scholar 

  80. Malatjalian DA, Graham CH: Liver adenoma with granulomas. The appearance of granulomas in oral contraceptive-related hepatocellular adenoma and in the surrounding nontumorous liver. Arch Pathol Lab Med 106:244–246, 1982

    Google Scholar 

  81. Bühler H, Pirovino M, Akovbiantz A, Altorfer J, Weitzel M, Maranta E, Schmid M: Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 82:775–782, 1982

    Google Scholar 

  82. Bartók I, Decastello A, Csikós F, Nagy I: Focal nodular hyperplasia of the liver and hepatic cell adenoma in women on oral contraceptives. Hepato-Gastroenterol 27:435–440, 1980

    Google Scholar 

  83. Steinberg H, Webb WM, Rafsky HA: Hepatomegaly with fatty infiltration, secondary to cortisone therapy: Case report. Gastroenterology 21:304–309, 1952

    Google Scholar 

  84. Taxy JB: Peliosis: A morphologic curiosity becomes an iatrogenic problem. Hum Pathol 9:331–340, 1978

    Google Scholar 

  85. Rosenberg JL, Edlow D, Sneider R: Liver disease and vasculitis in a patient taking cromolyn. Arch Intern Med 138:989–991, 1978

    Google Scholar 

  86. Klintmalm GBG, Iwatsuki S, Starzl TE: Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 32:488–489, 1981

    Google Scholar 

  87. Woods WG, Dehner LP, Nesbit ME, Krivit W, Coccia PF, Ramsay NKC, Kim TH, Kersey JH: Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation. Am J Med 68:285–290, 1980

    Google Scholar 

  88. Frosch PJ, Czarnetzki BM, Macher E, Grundmann E, Gottschalk I: Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J Cancer Res Clin Oncol 95:281–286, 1979

    Google Scholar 

  89. Runne U, Doepfmer K, Antz H, Groth W, Féaux de Lacroix W: Budd-Chiari-Syndrom unter Dacarbazin. Dtsch Med Wochenschr 105:230–233, 1980

    Google Scholar 

  90. Tolman KG, Hammar S, Sannella JJ: Possible hepatotoxicity of Doxidan. Ann Intern Med 84:290–292, 1976

    Google Scholar 

  91. Wilkinson SP, Portmann B, Williams R: Hepatitis from dantrolene sodium. Gut 20:33–36, 1979

    Google Scholar 

  92. Cornette M, Gillard C, Borlee-Hermans G: Hépatite toxique mortelle associée à l'usage du dantrolène. Acta Neurol Belg 80:336–347, 1980

    Google Scholar 

  93. Utili R, Boitnott JK, Zimmerman HJ: Dantrolene-associated hepatic injury. Gastroenterology 72:610–616, 1977

    Google Scholar 

  94. Ogburn RM, Myers RL, Burdick GE: Hepatitis associated with dantrolene sodium. Ann Intern Med 84:53–54, 1976 (letter)

    Google Scholar 

  95. Schneider R, Mitchell D: Dantrolene hepatitis. JAMA 235:1590–1591, 1976

    Google Scholar 

  96. Penta JS, Von Hoff DD, Muggia FM: Hepatotoxicity of combination chemotherapy for acute myelocytic leukemia. Ann Intern Med 87:247, 1977 (letter)

    Google Scholar 

  97. Powell WJ Jr, Koch-Weser J, Williams RA: Lethal hepatic necrosis after therapy with imipramine and desipramine. JAMA 206:642–644, 1968

    Google Scholar 

  98. Puppala AR, Ro JA: Possible association between peliosis hepatis and diethylstilbestrol. Report of two cases. Postgrad Med 65:277–281, 1979

    Google Scholar 

  99. Rosinus V, Maurer R: Diäthylstilböstrol-induziertes Leberzellkarzinom? Schweiz Med Wochenschr 111:1139–1142, 1981

    Google Scholar 

  100. Hoch-Ligeti C: Angiosarcoma of the liver associated with diethylstilbestrol. JAMA 240:1510–1511, 1978

    Google Scholar 

  101. Ham JM, Pirola RC, Crouch RL: Hemangioendothelial sarcoma of the liver associated with long-term estrogen therapy in a man. Dig Dis Sci 25:879–883, 1980

    Google Scholar 

  102. Doody PT: Disopyramide hepatotoxicity and disseminated intravascular coagulation. South Med J 75:496–498, 1978

    Google Scholar 

  103. Meinertz T, Langer KH, Kasper W, Just H: Disopyramide-induced intrahepatic cholestasis. Lancet 2:828–829, 1977 (letter)

    Google Scholar 

  104. Morris SJ, Kanner R, Chiprut RO, Schiff ER: Disulfiram hepatitis. Gastroenterology 75:100–102, 1978

    Google Scholar 

  105. Vázquez JJ, Pardo-Mindan J: Liver cell injury (bodies similar to Lafora's) in alcoholics treated with disulfiram (Antabuse). Histopathology 3:377–384, 1979

    Google Scholar 

  106. White LB, DeTarnowsky GO, Mir JA, Layden TJ: Hepatotoxicity following enflurane anesthesia. Dig Dis Sci 26:466–469, 1981

    Google Scholar 

  107. Ona FV, Patanella H, Ayub A: Hepatitis associated with enflurane anesthesia. Anesth Analg 59:146–149, 1980

    Google Scholar 

  108. Kline MM: Enflurane-associated hepatitis. Gastroenterology 79:126–127, 1980

    Google Scholar 

  109. Lloyd-Still JD, Sherman JO, Boggs J, Demers LM: Erythromycin estolate hepatotoxicity. Am J Dis Child 132:320, 1978

    Google Scholar 

  110. Zafrani ES, Ishak KG, Rudzki C: Cholestatic and hepato-cellular injury associated with erythromycin esters. Report of nine cases. Dig Dis Sci 24:385–396, 1979

    Google Scholar 

  111. Datey KK, Deshmukh SN, Dalvi CP, Purandare NM: Hepatocellular damage with ethacrynic acid. Br Med J 3:152–153, 1967

    Google Scholar 

  112. Conn HO, Binder HJ, Orr HD: Ethionamide-induced hepatitis. A review with a report of an additional case. Am Rev Respir Dis 90:542–552, 1964

    Google Scholar 

  113. Kuntz E, Liehr H, Pfingst W: Toxische Leberschädigung durch Äthionamid. Dtsch Med Wochenschr 92:1718–1722, 1967

    Google Scholar 

  114. Glazer SD, Roenigk HH Jr, Yokoo H, Sparberg M: A study of potential hepatotoxicity of etretinate used in the treatment of psoriasis. J Am Acad Dermatol 6:683–687, 1982

    Google Scholar 

  115. Wheby MS: Medicinal iron-induced hepatic cirrhosis: Reversal by phlebotomy: Studies on pathogenesis. Trans Am Clin Climatol Assoc 89:100–108, 1977

    Google Scholar 

  116. Nadell J, Kosek J: Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med 101:405–410, 1977

    Google Scholar 

  117. Falk H, Thomas LB, Popper H, Ishak KG: Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet 2:1120–1123, 1979

    Google Scholar 

  118. Snyder S: Fluphenazine jaundice. Report of a case. Am J Gastroenterol 73:336–340, 1980

    Google Scholar 

  119. Reynolds R, Lloyd DA, Slinger RP: Cholestatic jaundice induced by flurazepam hydrochloride. Can Med Assoc J 124:893–894, 1981

    Google Scholar 

  120. Fang MH, Ginsberg AL, Dobbins WO III Cholestatic jaundice associated with flurazepam hydrochloride. Ann Intern Med 89:363–364, 1978

    Google Scholar 

  121. Ghishan FK, LaBrecque DR, Younoszai K: Intrahepatic cholestasis after gold therapy in juvenile rheumatoid arthritis. J Pediatr 93:1042–1043, 1978

    Google Scholar 

  122. Griffin AJ: Cholestatic hepatitis induced by gold. Rheumatol Rehabil 18:174–176, 1979

    Google Scholar 

  123. Chiprut RO, Viteri A, Jamroz C, Dyck WP: Intrahepatic cholestasis after griseofulvin administration. Gastroenterology 70:1141–1143, 1976

    Google Scholar 

  124. Dincsoy HP, Saelinger DA: Haloperidol-induced chronic cholestatic liver disease. Gastroenterology 83:694–700, 1982

    Google Scholar 

  125. Hüttel MS: Halothane hepatitis after jejunoileal bypass. Acta Chir Scand 145:467–469, 1979

    Google Scholar 

  126. Touloukian J, Kaplowitz N: Halothane-induced hepatic disease. Semin Liver Dis 1:134–142, 1981

    Google Scholar 

  127. Thomas FB: Chronic aggressive hepatitis induced by halothane. Ann Intern Med 81:487–489, 1974

    Google Scholar 

  128. Klatskin G, Kimberg DV: Recurrent hepatitis attributable to halothane sensitization in an anesthetist. N Engl J Med 280:515–522, 1969

    Google Scholar 

  129. Gigase PL, Mortelmans J, Van Marck EAE: Nécrose hépatique mortelle après administration d'hycanthone. Ann Soc Belg Med Trop 59:431–434, 1979

    Google Scholar 

  130. Cohen C: Liver pathology in hycanthone hepatitis. Gastroenterology 75:103–106, 1978

    Google Scholar 

  131. Itoh S, Ichinoe A, Tsukada Y, Itoh Y: Hydralazine-induced hepatitis. Hepato-Gastroenterol 28:13–16, 1981

    Google Scholar 

  132. Itoh S, Yamaba Y, Ichinoe A, Tsukada Y: Hydralazine-induced liver injury. Dig Dis Sci 25:884–887, 1980

    Google Scholar 

  133. Bartoli E, Massarelli G, Solinas A, Faedda R, Chiandussi L: Acute hepatitis with bridging necrosis due to hydralazine intake. Report of a case. Arch Intern Med 139:698–699, 1979

    Google Scholar 

  134. Añez MS, Dickson G, Zabala R, Zabaleta P, Pacheco A, Briceño D: Hepatitis aguda por hidroclorotiacida. Presentación de un caso. Gastroenterol Hepatol 4:476–478, 1981

    Google Scholar 

  135. Bravo JF, Jacobson MP, Mertens BF: Fatty liver and pleural effusion with ibuprofen therapy. Ann Intern Med 87:200–201, 1977

    Google Scholar 

  136. Horst DA, Grace ND, LeCompte PM: Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology 79:550–554, 1980

    Google Scholar 

  137. Kelsey WM, Scharyj M: Fatal hepatitis probably due to indomethacin. JAMA 199:586–587, 1967

    Google Scholar 

  138. De Kraker-Sangster M, Bronkhorst FB, Brandt K-H, Boersma JW: Massale levercelnecrose na toediening van indometacine in combinatie met aminofenazon. Ned Tijdschr Geneeskd 125:1828–1831, 1981

    Google Scholar 

  139. Fenech FF, Bannister WH, Grech JL: Hepatitis with biliverdinaemia in association with indomethacin therapy. Br Med J 3:155–156, 1967

    Google Scholar 

  140. Sutherland LR, Edwards LA, Medline A, Wilkinson RW, Connon JJ: Meglumine iodipamide (Cholografin) hepatotoxicity: Ann Intern Med 86:437–439, 1977

    Google Scholar 

  141. Winckler K: Lebernekrosen nach Infusions-Cholangiographie. Dtsch Med Wochenschr 103:420–424, 1978

    Google Scholar 

  142. Ajdukiewicz AB, Grainger J, Scheuer PJ, Sherlock S: Jaundice due to iprindole. Gut 12:705–708, 1971

    Google Scholar 

  143. Pessayre D, De Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou J-P: Iproclozide fulminant hepatitis. Possible role of enzyme induction. Gastroenterology 75:492–496, 1978

    Google Scholar 

  144. Benack RT, Lynch V: Jaundice associated with isocarboxazid therapy. N Engl J Med 264:294–295, 1961

    Google Scholar 

  145. Bistritzer T, Barzilay Z, Jonas A: Isoniazid-rifampin-induced fulminant liver disease in an infant. J Pediatr 97:480–482, 1980

    Google Scholar 

  146. Maddrey WC: Isoniazid-induced liver disease. Semin Liver Dis 1:129–133, 1981

    Google Scholar 

  147. Graham WGB, Dundas GR: Isoniazid-related liver disease. Occurrence with portal hypertension, hypoalbuminemia, and hypersplenism. JAMA 242:353–354, 1979

    Google Scholar 

  148. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD: Isoniazid liver injury: Clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181–192, 1976

    Google Scholar 

  149. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69:289–302, 1975

    Google Scholar 

  150. Federal Drug Administration: Hepatotoxic potential of ketoconazole under investigation. FDA Drug Bull 12:11–12, 1982

    Google Scholar 

  151. Heiberg JK, Svejgaard E: Toxic hepatitis during ketoconazole treatment. Br Med J 283:825–826, 1981

    Google Scholar 

  152. Teychenne PF, Jones EA, Ishak KG, Calne DB: Hepatocellular injury with distinctive mitochondrial changes induced by lergotrile mesylate: A dopaminergic ergot derivative. Gastroenterology 76:575–583, 1979

    Google Scholar 

  153. Shapiro PA, Antonioli DA, Peppercorn MA: Barbiturate-induced submassive hepatic necrosis. Report of a case and review of the literature. Am J Gastroenterol 74:270–273, 1980

    Google Scholar 

  154. Krawitt EL, Stein JH, Kirkendall WM, Clifton JA: Mercaptopurine hepatotoxicity in a patient with chronic active hepatitis. Arch Intern Med 120:729–734, 1967

    Google Scholar 

  155. Bank JI, Lykkebo D, Hägerstrand I: Peliosis hepatis in a child. Acta Paediatr Scand 67:105–107, 1978

    Google Scholar 

  156. Johnson FL, Feagler JR, Lerner KG, Majerus PW, Siegel M, Hartmann JR, Thomas ED: Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 2:1273–1276, 1972

    Google Scholar 

  157. Becker CE, Gorden P, Robbins J: Hepatitis from methimazole during adrenal steroid therapy for malignant exophthalmos. JAMA 206:1787–1789, 1968

    Google Scholar 

  158. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD: Methotrexate guidelines—revised. J Am Acad Dermatol 6:145–155, 1982

    Google Scholar 

  159. Ruymann FB, Mosijczuk AD, Sayers RJ: Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA 238:2631–2633, 1977

    Google Scholar 

  160. Joshi PH, Conn HO: The syndrome of methoxyflurane-associated hepatitis. Ann Intern Med 80:395–401, 1974

    Google Scholar 

  161. Biellerup M, Bruze M, Hansson A, Krook C, Ljunggren B: Liver injury following administration of 8-methoxypsoralen during PUVA therapy. Acta Derm Venereol (Stockh) 59:371–372, 1979

    Google Scholar 

  162. Arranto AJ, Sotaniemi EA: Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short-and long-term exposure. Scand J Gastroenterol 16:853–863, 1981

    Google Scholar 

  163. Balázs M, Kovách G: Chronic aggressive hepatitis after methyldopa treatment. Case report with electron-microscopic study. Hepato-Gastroenterol 28:199–202, 1981

    Google Scholar 

  164. Hoyumpa AM Jr, Connell AM: Methyldopa hepatitis. Report of three cases. Am J Dig Dis 18:213–222, 1973

    Google Scholar 

  165. Tysell JE Jr, Knauer CM: Hepatitis induced by methyldopa (Aldomet). Report of a case and a review of the literature. Am J Dig Dis 16:849–855, 1971

    Google Scholar 

  166. Breland BD, Hicks GS Jr: Hepatitis and hemolytic anemia associated with methyldopa therapy. Drug Intell Clin Pharm 16:489–492, 1982

    Google Scholar 

  167. Brodén G, Bengtsson L: Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand (Suppl)500:7–12, 1980

    Google Scholar 

  168. Glober GA, Wilkerson JA: Biliary cirrhosis following the administration of methyltestosterone. JAMA 204:170–173, 1968

    Google Scholar 

  169. Paradinas FJ, Bull TB, Westaby D, Murray-Lyon IM: Hyperplasia and prolapse of hepatocytes into hepatic veins during longterm methyltestosterone therapy: Possible relationships of these changes to the development of peliosis hepatis and liver tumours. Histopathology 1:225–246, 1977

    Google Scholar 

  170. Cocks JR: Methyltestosterone-induced liver cell tumours. Med J Aust 2:617–618, 1981

    Google Scholar 

  171. Bird D, Vowles K, Anthony PP: Spontaneous rupture of a liver cell adenoma after long term methyltestosterone: Report of a case successfully treated by emergency right hepatic lobectomy. Br J Surg 66:212–213, 1979

    Google Scholar 

  172. Fraisse F, Marche C, Gibert C, Coquin Y, Vachon F: Nécrose hépatique aiguë et syndrome hémorragique mortel au décours d'une hypercalcémie traitée par la mithramycine. Ann Med Intern (Paris) 131:281–284, 1980

    Google Scholar 

  173. Moertel CG, Reitemeier RJ, Hahn RG: Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 204:1045–1048, 1968

    Google Scholar 

  174. Gottfried MR, Sudilovsky O: Hepatic veno-occlusive disease after high-dose mitomycin C and autologous bone marrow transplantation therapy. Hum Pathol 13:646–650, 1982

    Google Scholar 

  175. Victorino RMM, Silveira JCB, Baptista A, De Moura MC: Jaundice associated with naproxen. Postgrad Med J 56:368–370, 1980

    Google Scholar 

  176. Parsons WB Jr: Studies of nicotinic acid use in hypercholesteremia. Arch Intern Med 107:653–667, 1961

    Google Scholar 

  177. Berge KG, Achor RWP, Christensen NA, Mason HL, Barker NW: Hypercholesteremia and nicotinic acid. A long-term study. Am J Med 31:24–36, 1961

    Google Scholar 

  178. Kohn RM, Montes M: Hepatic fibrosis following long acting nicotinic acid therapy: A case report. Am J Med Sci 258:94–99, 1969

    Google Scholar 

  179. Sharp JR, Ishak KG, Zimmerman HJ: Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 92:14–19, 1980

    Google Scholar 

  180. Black M, Rabin L, Schatz N: Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med 92:62–64, 1980

    Google Scholar 

  181. Goldstein LI, Ishak KG, Burns W: Hepatic injury associated with nitrofurantoin therapy. Am J Dig Dis 19:987–998, 1974

    Google Scholar 

  182. Jokela S: Liver disease due to nitrofurantoin. Gastroenterology 53:306–311, 1967

    Google Scholar 

  183. Sippel PJ, Agger WA: Nitrofurantoin-induced granulomatous hepatitis. Urology 18:177–178, 1981

    Google Scholar 

  184. Anttinen H, Ahonen A, Leinonen A, Kallioinen M, Heikkinen ES: Diagnostic imaging of focal nodular hyperplasia of the liver developing during nitrofurantoin therapy. Acta Med Scand 211:227–232, 1982

    Google Scholar 

  185. Bruckstein AH, Attia AA: Oxacillin hepatitis. Two patients with liver biopsy and review of the literature. Am J Med 64:519–522, 1978

    Google Scholar 

  186. Pas AT, Quinn EL: Cholestatic hepatitis following the administration of sodium oxacillin. JAMA 191(8):138–139, 1965

    Google Scholar 

  187. Goldstein LI, Granoff M, Waisman J: Hepatic injury due to oxacillin administration. Am J Gastroenterol 70:171–174, 1978

    Google Scholar 

  188. Arnold GL, Kaplan MM: Peliosis hepatis due to oxymetholone—a clinically benign disorder. Am J Gastroenterol 71:213–216, 1979

    Google Scholar 

  189. Zevin D, Turani H, Cohen A, Levi J: Androgen-associated hepatoma in a hemodialysis patient. Nephron 29:274–276, 1981

    Google Scholar 

  190. Stromeyer FW, Smith DH, Ishak KG: Anabolic steroid therapy and intrahepatic cholangiocarcinoma. Cancer 43:440–443, 1979

    Google Scholar 

  191. Mulvihill JJ, Ridolfi RL, Schultz FR, Borzy MS, Haughton PBT: Hepatic adenoma in Fanconi anemia treated with oxymetholone. J Pediatr 87:122–124, 1975

    Google Scholar 

  192. Lundquist M: Discussion of paper by Sherlock S: Drugs and the liver.In Alcoholic Cirrhosis and Other Toxic Hepatopathies. A Engel, T Larsson (eds.) Stockholm, Nordiska Bokhandelns Förlag, 1970, pp 249–250

    Google Scholar 

  193. Kiaer HW, Olsen S, Rønnov-Jessen V: Hepatotoxicity of papaverine. Histologic lesions. Arch Pathol 98:292–296, 1974

    Google Scholar 

  194. Pathy MS, Reynolds AJ: Papaverine and hepatotoxicity. Postgrad Med J 56:488–490, 1980

    Google Scholar 

  195. Multz CV: Cholestatic hepatitis caused by penicillamine. JAMA 246:674–675, 1981

    Google Scholar 

  196. Job-Deslandre C, Delrieu F, Rondier J, Guedri M, Delbarre F: Hépatite cholestatique et anticorps anti-DNA induits par la D-pénicillamine. Nouv Presse Med 11:2356–2357, 1982

    Google Scholar 

  197. Williams CN, Malatjalian DA: Severe penicillin-induced cholestasis in a 91-year-old woman. Dig Dis Sci 26:470–473, 1981

    Google Scholar 

  198. Forbes GB, Rake MO, Taylor DJE: Liver damage due to perhexiline maleate. J Clin Pathol 32:1282–1285, 1979

    Google Scholar 

  199. Poupon R, Rosensztajn L, Prudhomme de Saint Maur P, Lageron A, Gombeau T, Darnis F: Perhexiline maleateassociated hepatic injury prevalence and characteristics. Digestion 20:145–150, 1980

    Google Scholar 

  200. Pessayre D, Bichara M, Feldmann G, Degott C, Potet F, Benhamou J-P: Perhexiline maleate-induced cirrhosis. Gastroenterology 76:170–177, 1979

    Google Scholar 

  201. Heathfield KWG, Carabott F: Adverse effects of perhexiline. Lancet 1:507–508, 1982 (letter)

    Google Scholar 

  202. Berkowitz D, Rotman M, Greenstein RH, Sloane NG: Occurrence of jaundice during treatment with perphenazine and beta-phenylisopropylhydrazine. Am J Dig Dis 6:160–165, 1961

    Google Scholar 

  203. Goldfinger SE, Marx S: Hypersensitivity hepatitis due to phenazopyridine hydrochloride. N Engl J Med 286:1090–1091, 1972

    Google Scholar 

  204. Cook GC, Sherlock S: Jaundice and its relation to therapeutic agents. Lancet 1:175–179, 1965

    Google Scholar 

  205. Daneshmend TK, Scott GL, Bradfield JWB: Angiosarcoma of liver associated with phenelzine. Br Med J 1:1679, 1979

    Google Scholar 

  206. McGeachy TE, Bloomer WE: The phenobarbital sensitivity syndrome. Am J Med 14:600–604, 1953

    Google Scholar 

  207. Pagliaro L, Campesi G, Aguglia F: Barbiturate jaundice. Report of a case due to a barbital-containing drug, with positive rechallenge to phenobarbital. Gastroenterology 56:938–943, 1969

    Google Scholar 

  208. Benjamin SB, Ishak KG, Zimmerman HJ, Grushka A: Phenylbutazone liver injury: A clinical-pathologic survey of 23 cases and review of the literature. Hepatology 1:255–263, 1981

    Google Scholar 

  209. van de Merwe JP, van Blankenstein M, Wilson JHP: Intrahepatic cholestasis induced by phenylbutazone. Digestion 22:317–320, 1981

    Google Scholar 

  210. Engleman EP, Krupp MA, Rinehart JF, Jones RC, Gibson JR: Hepatitis following the ingestion of phenylbutazone. JAMA 156:98–101, 1954

    Google Scholar 

  211. Lee TJ, Carney CN, Lapis JL, Higgins T, Fallon HJ: Diphenylhydantoin-induced hepatic necrosis. A case study. Gastroenterology 70:422–424, 1976

    Google Scholar 

  212. Harinasuta U, Zimmerman HJ: Diphenylhydantoin sodium hepatitis. JAMA 203(12):111–114, 1968

    Google Scholar 

  213. Spechler SJ, Sperber H, Doos WG, Koff RS: Cholestasis and toxic epidermal necrolysis associated with phenytoin sodium ingestion: The role of bile duct injury. Ann Intern Med 95:455–456, 1981

    Google Scholar 

  214. Cook IF, Shilkin KB, Reed WD: Phenytoin induced granulomatous hepatitis. Aust NZ J Med 11:539–541, 1981

    Google Scholar 

  215. Hamlyn AN, Morris JS, Sarkany I, Sherlock S: Piperazine hepatitis. Gastroenterology 70:1144–1147, 1976

    Google Scholar 

  216. Brown PJE, Lesna M, Hamlyn AN, Record CO: Primary biliary cirrhosis after long-term practolol administration. Br Med J 1:1591, 1978

    Google Scholar 

  217. Reynolds ES, Schlant RC, Gonick HC, Dammin GJ: Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid. N Engl J Med 256:592–596, 1957

    Google Scholar 

  218. Rotmensch HH, Yust I, Siegman-Igra Y, Liron M, Ilie B, Vardinon N: Granulomatous hepatitis: A hypersensitivity response to procainamide. Ann Intern Med 89:646–647, 1978

    Google Scholar 

  219. McFarland RB: Fatal drug reaction associated with prochlorperazine (Compazine). Am J Clin Pathol 40:284–290, 1963

    Google Scholar 

  220. Mechanic RC, Meyers L: Chlorpromazine-type cholangitis. Report of a case occurring after the administration of prochlorperazine. N Engl J Med 259:778–780, 1958

    Google Scholar 

  221. Weinstein A, Alper BJ, Dade JR: Cholestasis due to prochlorperazine. JAMA 170:1663–1664, 1959

    Google Scholar 

  222. Klein NC, Magida MG: Propoxyphene (Darvon) hepatotoxicity. Am J Dig Dis 16:467–469, 1971

    Google Scholar 

  223. Eisen MJ: Fulminant hepatitis during treatment with propylthiouracil. N Engl J Med 249:814–816, 1953

    Google Scholar 

  224. Mihas AA, Holley P, Koff RS, Hirschowitz BI: Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 70:770–774, 1976

    Google Scholar 

  225. Fedotin MS, Lefer LG: Liver disease caused by propylthiouracil. Arch Intern Med 135:319–321, 1975

    Google Scholar 

  226. Hutchison JC, Roediger PM, Werblin M: Cholestatic jaundice following administration of quinethazone. Curr Ther Res 6:199–201, 1964

    Google Scholar 

  227. Koch MJ, Seeff LB, Crumley CE, Rabin L, Burns WA: Quinidine hepatotoxicity. A report of a case and review of the literature. Gastroenterology 70:1136–1140, 1976

    Google Scholar 

  228. Bramlet DA, Posalaky Z, Olson R: Granulomatous hepatitis as a manifestation of quinidine hypersensitivity. Arch Intern Med 140:395–397, 1980

    Google Scholar 

  229. Pessayre D, Bentata M, Degott C, Nouel O, Miguet J-P, Rueff B, Benhamou J-P: Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 72:284–289, 1977

    Google Scholar 

  230. Poupon RY, Meyniel D, Petit J, Gustot P, Darnis F: Hépatite cholestatique au cours d'un traitement par l'I.N.H. et la rifampicine: Arguments en faveur de l'hépatotoxicité de la rifampicine. Ann Med Intern (Paris) 130:371–375, 1979

    Google Scholar 

  231. Shuck J, Shen S, Owensby L, Leftik M, Cucinell S: Spironolactone hepatitis in primary hyperaldosteronism. Ann Intern Med 95:708–710, 1981

    Google Scholar 

  232. Eklöf B, Gjöres JE, Lohi A, Norgren L, Staszkiewicz: Spontan ruptur av lever och mjälte vid streptokinasbehandling av djup ventrombos. Lakartidningen 75:777–778, 1978

    Google Scholar 

  233. Herbut PA, Scaricaciottoli TM: Diffuse hepatic necrosis caused by sulfadiazine. Arch Pathol 40:94–98, 1945

    Google Scholar 

  234. Tönder M, Nordöy A, Elgjo K: Sulfonamide-induced chronic liver disease. Scand J Gastroenterol 9:93–96, 1974

    Google Scholar 

  235. Ransohoff DF, Jacobs G: Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology 80:816–819, 1981

    Google Scholar 

  236. Steinbrecher UP, Mishkin S: Sulfamethoxazole-induced hepatic injury. Dig Dis Sci 26:756–759, 1981

    Google Scholar 

  237. Stewart DL, Johnson RC: Acute hepatitis caused by sulfamethoxazole-trimethoprim. Gastroenterology 78:1323, 1980 (abstract)

    Google Scholar 

  238. Sotolongo RP, Neefe LI, Rudzki C, Ishak KG: Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity: Gastroenterology 75:95–99, 1978

    Google Scholar 

  239. Losek JD, Werlin SL: Sulfasalazine hepatotoxicity: Am J Dis Child 135:1070–1072, 1981

    Google Scholar 

  240. Namias A, Bhalotra R, Donowitz M: Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol 3:193–198, 1981

    Google Scholar 

  241. Smith MD, Gibson GE, Rowland R: Combined hepatotoxicity and neurotoxicity following sulphasalazine administration. Aust NZ J Med 12:76–80, 1982

    Google Scholar 

  242. More RH, McMillan GC, Duff GL: The pathology of sulfonamide allergy in man. Am J Pathol 22:703–725, 1946

    Google Scholar 

  243. Zimmerman HJ: Drug-induced chronic hepatic disease. Med Clin North Am 63:567–582, 1979

    Google Scholar 

  244. Iwarson S, Lundin P: Multiple attacks of jaundice associated with repeated sulfonamide treatment. Acta Med Scand 206:219–222, 1979

    Google Scholar 

  245. Park GD, Spector R, Headstream T, Goldberg M: Serious adverse reactions associated with sulindac. Arch Intern Med 142:1292–1294, 1982

    Google Scholar 

  246. Whittaker SJ, Amar JN, Wanless IR, Heathcote J: Sulindac hepatotoxicity. Gut 23:875–877, 1982

    Google Scholar 

  247. Giroux Y, Moreau M, Kass TG: Cholestatic jaundice caused by sulindac. Can J Surg 25:334–335, 1982

    Google Scholar 

  248. Sale GE, Lerner KG: Multiple tumors after androgen therapy. Arch Pathol Lab Med 101:600–603, 1977

    Google Scholar 

  249. Jalota R, Freston JW: Severe intrahepatic cholestasis due to thiabendazole. Am J Trop Med Hyg 23:676–678, 1974

    Google Scholar 

  250. Gill RA, Onstad GR, Cardamone JM, Maneval DC, Sumner HW: Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 96:58–60, 1982

    Google Scholar 

  251. Hasselstrøm L, Kristoffersen MB: Hepatitis following thiopentone. A case report. Br J Anaesth 51: 801–804, 1979

    Google Scholar 

  252. Reinhart MJ, Benson RM, Kwass SK, Storey WF: Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use. JAMA 197(10):113–115, 1966

    Google Scholar 

  253. Bridges ME, Pittman FE: Tolazamide-induced cholestasis. South Med J 73:1072–1074, 1980

    Google Scholar 

  254. LoIudice TA, Lang JA: Tolazamide-induced hepatic dysfunction. Am J Gastroenterol 69:81–83, 1978

    Google Scholar 

  255. Hamff LH, Ferris HA, Evans EC, Whiteman HW: The effects of tolbutamide and chlorpropamide on patients exhibiting jaundice as a result of previous chlorpropamide therapy. Ann NY Acad Sci 74:820–829, 1959

    Google Scholar 

  256. Gregory DH, Zaki GF, Sarcosi GA, Carey JB Jr: Chronic cholestasis following prolonged tolbutamide administration. Associated with destructive cholangitis and cholangiolitis. Arch Pathol 84:194–201, 1967

    Google Scholar 

  257. Bandt C, Hoffbauer FW: Liver injury associated with tranylcypromine therapy. JAMA 188:752–753, 1964

    Google Scholar 

  258. Cobden I, Record CO, White RWB: Fatal intrahepatic cholestasis associated with triazolam. Postgrad Med J 57:730–731, 1981

    Google Scholar 

  259. Kohn N, Myerson RM: Cholestatic hepatitis associated with trifluoperazine. N Engl J Med 264:549–550, 1961

    Google Scholar 

  260. Borda I, Jick H: Hepatitis following the administration of trimethobenzamide hydrochloride. Arch Intern Med 120:371–373, 1967

    Google Scholar 

  261. Coto H, McGowan WR, Pierce EH Jr, Thomas E: Intrahepatic cholestasis due to trimethoprim-sulfamethoxazole. South Med J 74:897–898, 1981

    Google Scholar 

  262. Bjørneboe M, Iversen O, Olsen S: Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period. Incidence and prognosis. Acta Med Scand 182:491–501, 1967

    Google Scholar 

  263. Zimmerman HJ, Ishak KG: Valproate-induced hepatic injury: Analyses of 23 fatal cases. Hepatology 2:591–597, 1982

    Google Scholar 

  264. Dizadji H, Hammer R, Strzyz B, Weisenberger J: Spontaneous rupture of the liver. A complication of oral anticoagulant therapy. Arch Surg 114:734–735, 1979

    Google Scholar 

  265. Rehnqvist N: Intrahepatic jaundice due to warfarin therapy. Acta Med Scand 204:335–336, 1978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Section of Medical Pathology, Mayo Clinic, 55905, Rochester, Minnesota

    Jurgen Ludwig MD & Rebecca Axelsen RPh

  2. Mayo Foundation, 55905, Rochester, Minnesota

    Jurgen Ludwig MD & Rebecca Axelsen RPh

  3. Pharmacy Services, St. Marys Hospital, Rochester, Minnesota

    Jurgen Ludwig MD & Rebecca Axelsen RPh

Authors
  1. Jurgen Ludwig MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca Axelsen RPh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ludwig, J., Axelsen, R. Drug effects on the liver. Digest Dis Sci 28, 651–666 (1983). https://doi.org/10.1007/BF01299927

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01299927

Keywords

Search

Navigation